ENDPOINTS

AstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneron

AstraZeneca is further investing in China, opening an R&D center in Beijing and inking a pair of majorly backloaded R&D deals with Chinese drug developers. The Harbour BioMed and Syneron Bio deals are each potentially ...

Mar 21, 2025 - 16:20
 0
AstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneron
AstraZeneca is further investing in China, opening an R&D center in Beijing and inking a pair of majorly backloaded R&D deals with Chinese drug developers. The Harbour BioMed and Syneron Bio deals are each potentially ...
Read More

Tags:

Previous Article

Are you protected against measles? Do you need a booster shot? Everything you ne...

Next Article

AstraZeneca earmarks $2.5B for first vaccine factory and second R&D site in China

Related Posts

Arcus touts early kidney cancer data as Gilead declines option

Arcus touts early kidney cancer data as Gilead declines...

Feb 18, 2025  0

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Pfizer wants in on Summit’s goal to beat Keytruda via A...

Feb 24, 2025  0

Ascletis’ obesity pill looks similar to Roche’s drug, early data suggest

Ascletis’ obesity pill looks similar to Roche’s drug, e...

Feb 19, 2025  0